Academy President Donald W. Landry presents the American Academy of Sciences and Letters medal to Winthrop P. Rockefeller Cancer Institute Director Michael Birrer.Michael J. Birrer, director of the Winthrop P. Rockefeller Cancer Institute at the University of Medical Sciences, has been inducted as a member of the American Academy of Sciences and Letters.
Onboard AI and Cedars-Sinai will collaborate to deploy an automated, AI-native governance platform that health systems can use to streamline and strengthen the evaluation, approval, and monitoring of AI solutions.
UCLA Health has established the Department of Nuclear Medicine and Theranostics—the first of its kind in the United States. The new department will integrate advanced imaging and therapy, accelerate scientific discovery, and advance precision health at UCLA Health.
ChristianaCare’s Cawley Center for Translational Cancer Research has established an organoid core.
The governing board of the Cancer Prevention and Research Institute of Texas met in Austin on Nov. 19 and approved 73 grants totaling almost $154 million.
GLP-1 receptor agonists—the class of drugs behind Ozempic, Wegovy, and Mounjaro—may do more than regulate blood sugar and weight.
About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a KFF Health Tracking Poll finds.
Clinician-scientists at St. Jude Children’s Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma ever reported, uncovering key factors that could be used to guide treatment strategies for this rare pediatric brain tumor.
A collaborative research team, led by scientists at VCU Massey Comprehensive Cancer Center and Huntsman Cancer Institute at the University of Utah, has identified a targeted drug that could effectively treat an aggressive soft tissue cancer that occurs most often in pediatric and young adult patients.
Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial.
